Cargando…

Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines

BACKGROUND & AIMS: Case reports of severe acute liver injury (ALI) following COVID-19 vaccination have recently been published. We evaluated the risks of ALI following COVID-19 vaccination (BNT162b2 or CoronaVac). METHODS: We conducted a modified self-controlled case series analysis using the va...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Carlos King Ho, Mak, Lung Yi, Au, Ivan Chi Ho, Lai, Francisco Tsz Tsun, Li, Xue, Wan, Eric Yuk Fai, Chui, Celine Sze Ling, Chan, Esther Wai Yin, Cheng, Wing Yiu, Cheng, Franco Wing Tak, Yuen, Man Fung, Wong, Ian Chi Kei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Association for the Study of the Liver. Published by Elsevier B.V. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376738/
https://www.ncbi.nlm.nih.gov/pubmed/35817224
http://dx.doi.org/10.1016/j.jhep.2022.06.032
_version_ 1784768198275497984
author Wong, Carlos King Ho
Mak, Lung Yi
Au, Ivan Chi Ho
Lai, Francisco Tsz Tsun
Li, Xue
Wan, Eric Yuk Fai
Chui, Celine Sze Ling
Chan, Esther Wai Yin
Cheng, Wing Yiu
Cheng, Franco Wing Tak
Yuen, Man Fung
Wong, Ian Chi Kei
author_facet Wong, Carlos King Ho
Mak, Lung Yi
Au, Ivan Chi Ho
Lai, Francisco Tsz Tsun
Li, Xue
Wan, Eric Yuk Fai
Chui, Celine Sze Ling
Chan, Esther Wai Yin
Cheng, Wing Yiu
Cheng, Franco Wing Tak
Yuen, Man Fung
Wong, Ian Chi Kei
author_sort Wong, Carlos King Ho
collection PubMed
description BACKGROUND & AIMS: Case reports of severe acute liver injury (ALI) following COVID-19 vaccination have recently been published. We evaluated the risks of ALI following COVID-19 vaccination (BNT162b2 or CoronaVac). METHODS: We conducted a modified self-controlled case series analysis using the vaccination records in Hong Kong with data linkage to electronic medical records from a territory-wide healthcare database. Incidence rate ratios (IRRs) for ALI outcome in the 56-day period following first and second doses of COVID-19 vaccines in comparison to the non-exposure period were estimated and compared to the ALI risk in patients with SARS-CoV-2 infection. RESULTS: Among 2,343,288 COVID-19 vaccine recipients who were at risk, 4,677 patients developed ALI for the first time between 23(rd) February 2021 to 30(th) September 2021. The number of ALI cases within 56 days after the first and second dose of vaccination were 307 and 521 (335 and 334 per 100,000 person-years) for BNT162b2, and 304 and 474 (358 and 403 per 100,000 person-years) for CoronaVac, respectively, compared to 32,997 ALI cases per 100,000 person-years among patients within 56 days of SARS-CoV-2 infection. Compared to the non-exposure period, no increased risk was observed in the 56-day risk period for first (IRR 0.800; 95% CI 0.680–0.942) and second (IRR 0.944; 95% CI 0.816–1.091) dose of BNT162b2, or first (IRR 0.689; 95% CI 0.588–0.807) and second (IRR 0.905; 95% CI 0.781–1.048) dose of CoronaVac. There were no severe or fatal cases of ALI following COVID-19 vaccination. CONCLUSION: There was no evidence of an increased risk of ALI associated with BNT162b2 or CoronaVac vaccination. Based on all current available evidence from previous studies and our study, the benefit of mass vaccination far outweighs the ALI risk from vaccination. LAY SUMMARY: There have been some recent reports that COVID-19 vaccination could be associated with acute liver injury. In our study, we found no evidence that COVID-19 vaccination increased the risk of acute liver injury, which was much more common after SARS-CoV-2 infection than after vaccination. Hence, our study provides further data indicating that the benefits of mass COVID-19 vaccination outweigh the potential risks.
format Online
Article
Text
id pubmed-9376738
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Association for the Study of the Liver. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-93767382022-08-17 Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines Wong, Carlos King Ho Mak, Lung Yi Au, Ivan Chi Ho Lai, Francisco Tsz Tsun Li, Xue Wan, Eric Yuk Fai Chui, Celine Sze Ling Chan, Esther Wai Yin Cheng, Wing Yiu Cheng, Franco Wing Tak Yuen, Man Fung Wong, Ian Chi Kei J Hepatol Research Article BACKGROUND & AIMS: Case reports of severe acute liver injury (ALI) following COVID-19 vaccination have recently been published. We evaluated the risks of ALI following COVID-19 vaccination (BNT162b2 or CoronaVac). METHODS: We conducted a modified self-controlled case series analysis using the vaccination records in Hong Kong with data linkage to electronic medical records from a territory-wide healthcare database. Incidence rate ratios (IRRs) for ALI outcome in the 56-day period following first and second doses of COVID-19 vaccines in comparison to the non-exposure period were estimated and compared to the ALI risk in patients with SARS-CoV-2 infection. RESULTS: Among 2,343,288 COVID-19 vaccine recipients who were at risk, 4,677 patients developed ALI for the first time between 23(rd) February 2021 to 30(th) September 2021. The number of ALI cases within 56 days after the first and second dose of vaccination were 307 and 521 (335 and 334 per 100,000 person-years) for BNT162b2, and 304 and 474 (358 and 403 per 100,000 person-years) for CoronaVac, respectively, compared to 32,997 ALI cases per 100,000 person-years among patients within 56 days of SARS-CoV-2 infection. Compared to the non-exposure period, no increased risk was observed in the 56-day risk period for first (IRR 0.800; 95% CI 0.680–0.942) and second (IRR 0.944; 95% CI 0.816–1.091) dose of BNT162b2, or first (IRR 0.689; 95% CI 0.588–0.807) and second (IRR 0.905; 95% CI 0.781–1.048) dose of CoronaVac. There were no severe or fatal cases of ALI following COVID-19 vaccination. CONCLUSION: There was no evidence of an increased risk of ALI associated with BNT162b2 or CoronaVac vaccination. Based on all current available evidence from previous studies and our study, the benefit of mass vaccination far outweighs the ALI risk from vaccination. LAY SUMMARY: There have been some recent reports that COVID-19 vaccination could be associated with acute liver injury. In our study, we found no evidence that COVID-19 vaccination increased the risk of acute liver injury, which was much more common after SARS-CoV-2 infection than after vaccination. Hence, our study provides further data indicating that the benefits of mass COVID-19 vaccination outweigh the potential risks. European Association for the Study of the Liver. Published by Elsevier B.V. 2022-11 2022-07-09 /pmc/articles/PMC9376738/ /pubmed/35817224 http://dx.doi.org/10.1016/j.jhep.2022.06.032 Text en © 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Research Article
Wong, Carlos King Ho
Mak, Lung Yi
Au, Ivan Chi Ho
Lai, Francisco Tsz Tsun
Li, Xue
Wan, Eric Yuk Fai
Chui, Celine Sze Ling
Chan, Esther Wai Yin
Cheng, Wing Yiu
Cheng, Franco Wing Tak
Yuen, Man Fung
Wong, Ian Chi Kei
Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines
title Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines
title_full Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines
title_fullStr Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines
title_full_unstemmed Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines
title_short Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines
title_sort risk of acute liver injury following the mrna (bnt162b2) and inactivated (coronavac) covid-19 vaccines
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376738/
https://www.ncbi.nlm.nih.gov/pubmed/35817224
http://dx.doi.org/10.1016/j.jhep.2022.06.032
work_keys_str_mv AT wongcarloskingho riskofacuteliverinjuryfollowingthemrnabnt162b2andinactivatedcoronavaccovid19vaccines
AT maklungyi riskofacuteliverinjuryfollowingthemrnabnt162b2andinactivatedcoronavaccovid19vaccines
AT auivanchiho riskofacuteliverinjuryfollowingthemrnabnt162b2andinactivatedcoronavaccovid19vaccines
AT laifranciscotsztsun riskofacuteliverinjuryfollowingthemrnabnt162b2andinactivatedcoronavaccovid19vaccines
AT lixue riskofacuteliverinjuryfollowingthemrnabnt162b2andinactivatedcoronavaccovid19vaccines
AT wanericyukfai riskofacuteliverinjuryfollowingthemrnabnt162b2andinactivatedcoronavaccovid19vaccines
AT chuicelineszeling riskofacuteliverinjuryfollowingthemrnabnt162b2andinactivatedcoronavaccovid19vaccines
AT chanestherwaiyin riskofacuteliverinjuryfollowingthemrnabnt162b2andinactivatedcoronavaccovid19vaccines
AT chengwingyiu riskofacuteliverinjuryfollowingthemrnabnt162b2andinactivatedcoronavaccovid19vaccines
AT chengfrancowingtak riskofacuteliverinjuryfollowingthemrnabnt162b2andinactivatedcoronavaccovid19vaccines
AT yuenmanfung riskofacuteliverinjuryfollowingthemrnabnt162b2andinactivatedcoronavaccovid19vaccines
AT wongianchikei riskofacuteliverinjuryfollowingthemrnabnt162b2andinactivatedcoronavaccovid19vaccines